AZN

Astrazeneca plc - ADR

Healthcare


Presented:12/19/2023
Price:$65.90
Cap:$204.28B
Current Price:$77.85
Cap:$241.38B

Presented

Date12/19/2023
Price$65.90
Market Cap$204.28B
Ent Value$234.77B
P/E Ratio34.63x
Book Value$12.00
Div Yield2.2%
Shares O/S3,099.86M
Ave Daily Vol5,679,835
Short IntN/A

Current

Price$77.85
Market Cap$241.38B
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Publicly traded companies mentioned herein: AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Merck (MRK), Novartis (NVS), Roche (ROG), Thermo Fisher Scientific (TMO)

Highlights

The presenter is long shares of AstraZeneca (AZN), due to its strong fundamentals in oncology, potential EPS growth, and favorable valuation. Unlike many pharmaceutical companies facing patent cliffs or limitations, AstraZeneca is well-positioned to see sustained growth from its diversified pipeline and a more stable generics environment. The presenter expects these factors to drive high single-digit topline growth and mid-teen EPS growth through the end of the decade. This could be reflected in consensus EPS resets within the next 12 months as upcoming products launch (Ehertu & Dato-DXd). The upgraded earnings and a slight rerating in the forward EPS multiple to 18x from 16x could result in a 40% return.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.